



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/886,779	06/21/2001	Chandran R. Sabanayagam	701586/50113-C	6933
26248	7590	10/22/2003	EXAMINER	
NIXON PEABODY LLP 101 FEDERAL ST BOSTON, MA 02110			LU, FRANK WEI MIN	
			ART UNIT	PAPER NUMBER
			1634	

DATE MAILED: 10/22/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/886,779	SABANAYAGAM ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Frank W Lu	1655	

-- The MAILING DATE of this communication appears on the cover sheet with the corresponding address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 8/1/2003.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 11 and 23-33 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 11 and 23-33 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 8/1/2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

### Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                  | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____  |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-943)         | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: _____                                    |

Art Unit: 1634

## **DETAILED ACTION**

### ***Continued Examination***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 1, 2003 has been entered. The claims pending in this application are claims 11 and 23-33. Rejection and/or objection not reiterated from the previous office action are hereby withdrawn in view of the amendment filed on August 1, 2003.

### ***Claim Objections***

2. Claim 11 is objected to because of the following informality: "wherein said ordered redundant array refers to said array having each extended immobilized oligonucleotide comprise at least two copies of said sequence of interest along the z coordinate" in step d) should be "wherein said ordered redundant array refers to said array having each extended immobilized oligonucleotide comprising at least two copies of said sequence of interest along the z coordinate".

3. Claim 23 is objected to because of the following informality: wherein said ordered redundant array refers to said array having each extended immobilized oligonucleotide comprise at least two copies along the z coordinate of said portion of the sequence of interest contained in said primed circular template" in step d) should be "wherein said ordered redundant array refers

Art Unit: 1634

to said array having each extended immobilized oligonucleotide comprising at least two copies of said portion of the sequence of interest contained in said primed circular template along the z coordinate”.

Appropriate correction is required.

***Claim Rejections - 35 USC § 102***

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

5. Claims 11 and 23-33 are rejected under 35 U.S.C. 102(b) as being anticipated by Smith *et al.*, (US Patent No. 5,753,439, filed on May 19, 2003).

Smith *et al.*, teach arrays of probes. Each probe in the array comprised a constant 5'-region, a constant 3'-region and a variable internal region wherein the variable region comprised one or more repeat sequences. The repeat sequence comprised heterologous or homologous sequences which were variable in length or base sequence. Sequences contained purine or pyrimidine bases or neutral bases such as inosine. Either the nucleic acids or the probes of the array were labeled with a detectable label or fixed to a solid support. Probes were single-stranded or partly single-stranded and partly double-stranded. Arrays comprised between about 10 to about

Art Unit: 1634

10,000 different probes (see column 9, lines 18-34). In certain situation, the repeat sequences are about 2 to about 2000 (see column 15, claims 1 and 2).

Regarding claims 11 and 23, since claims 11 and 23 are directed to a product (an ordered redundant array of immobilized oligonucleotides) and are not directed to a method, the method steps recited in claims 11 and 23 which are used to make the ordered redundant array of immobilized oligonucleotides are no patentable weight and claims 11 and 23 are product-by-process claims. Note that it is well established that even though product-by process claims are limited by and defined by the process, the determination of the patentability of the product is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." *In re Thorpe*, 227 USPQ 964, 966 (Fed. Cir. 1985). Since claims 11 and 23 are directed an ordered redundant array of extended immobilized oligonucleotides wherein each extended immobilized oligonucleotide comprises at least two copies of sequence of interest along the z coordinate while Smith *et al.*, teach an array comprising 10 to 10,000 different probes with 2-2000 repeats (see column 9, lines 18-34 and column 15, claims 1 and 2), an ordered redundant array of extended immobilized oligonucleotides wherein each extended immobilized oligonucleotide comprises at least two copies of sequence of interest as recited in claims 11 and 23 is anticipated by Smith *et al.*. The probes on the array taught by Smith *et al.*, are considered to be along the Z coordinate since each of these probes from one end to another end has 5' to 3'

Art Unit: 1634

direction. Furthermore, applicant has no evidence to indicate that these probes on the array taught by Smith *et al.*, are not along the Z coordinate.

Regarding claim 30, claim 30 is directed an ordered redundant array of extended immobilized oligonucleotides wherein each extended immobilized oligonucleotide comprises at least two copies of sequence of interest along the z coordinate and each sequence of interest is different for each extended immobilized oligonucleotides. Since Smith *et al.*, teach an array comprising 10 to 10,000 different probes with 2-2000 repeats wherein the repeat sequences comprise heterologous sequences which are variable in length or base sequence (see column 9, lines 18-34 and column 15, claims 1 and 2), Smith *et al.*, teach an ordered redundant array of extended immobilized oligonucleotides wherein each extended immobilized oligonucleotide comprises at least two copies of sequence of interest and each sequence of interest is different and can bind to a different target nucleic acid. The probes on the array taught by Smith *et al.*, are considered to be along the Z coordinate since each of these probes from one end to another end has 5' to 3' direction. Furthermore, applicant has no evidence to indicate that these probes on the array taught by Smith *et al.*, are not along the Z coordinate.

Regarding claims 24-29 and 31-33, since these different probes taught by Smith *et al.*, have 2-2000 repeats, claims 24-29 and 31-33 are anticipated by Smith *et al.*.

Therefore, Smith *et al.*, teach all limitations recited in claims 11 and 23-33.

Art Unit: 1634

***Response to Arguments***

6. Applicant's arguments with respect to claims 11 and 23-33 have been considered but are moot in view of the new ground(s) of rejection.

***Conclusion***


7. No claim is allowed.

8. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is either (703) 308-4242 or (703)305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (703) 305-1270. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152.

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

  
Frank Lu (PSA)  
October 17, 2003